Kura Oncology Inc

NASDAQ KURA

Data sourced from

and

Download Data

Kura Oncology Inc Operating Income to Total Debt for the year ending December 31, 2023: -15.30

Kura Oncology Inc Operating Income to Total Debt is -15.30 for the year ending December 31, 2023, a -24.85% change year over year. The operating income to total debt ratio measures the ability of a company's operating income to cover its total debt obligations. It is calculated by dividing the operating income by the total debt. This ratio provides insights into the company's ability to generate income from its operations to service its debt. A higher ratio indicates a stronger capacity to generate operating income relative to the level of debt, suggesting potential financial strength and debt servicing capability.

Kura Oncology Inc Operating Income to Total Debt for the year ending December 31, 2022 was -12.25.
Kura Oncology Inc Operating Income to Total Debt for the year ending December 31, 2020 was -9.86, a -9.60% change year over year.
Kura Oncology Inc Operating Income to Total Debt for the year ending December 31, 2019 was -9.00.

NASDAQ: KURA

Kura Oncology Inc

CEO	Dr. Troy Edward Wilson J.D., Ph.D.
IPO Date	Sept. 22, 2015
Location	United States
Headquarters	12730 High Bluff Drive, San Diego, CA, United States, 92130
Employees	142
Sector	Healthcare
Industry	Biotechnology

Description

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Key trends